One research demonstrates that using the lipophilic ligand painting strategy, Lipophilic anti-CD45 and anti-CD20 (Rituximab) surface painted RBCs could be in one step converted into targeted entities that efficiently and specifically bind to CD45 positive leukocytes and CD19+/CD20+/CD45+ human lymphoma cells in vitro and in vivo, inducing therapeutic effect in the mouse model of lymphoma (Mukthavaram et al., 2014). The gene discussed is PTPRC; the disease is lymphoma.